Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Angiodynamics (ANGO) over the last 17 years, with Q4 2025 value amounting to $5.7 million.

  • Angiodynamics' Depreciation & Amortization (CF) fell 1626.11% to $5.7 million in Q4 2025 from the same period last year, while for Nov 2025 it was $23.9 million, marking a year-over-year decrease of 1453.53%. This contributed to the annual value of $25.8 million for FY2025, which is 689.95% down from last year.
  • Latest data reveals that Angiodynamics reported Depreciation & Amortization (CF) of $5.7 million as of Q4 2025, which was down 1626.11% from $6.0 million recorded in Q3 2025.
  • In the past 5 years, Angiodynamics' Depreciation & Amortization (CF) ranged from a high of $7.8 million in Q1 2023 and a low of $5.7 million during Q4 2025
  • For the 5-year period, Angiodynamics' Depreciation & Amortization (CF) averaged around $6.9 million, with its median value being $6.8 million (2024).
  • Per our database at Business Quant, Angiodynamics' Depreciation & Amortization (CF) skyrocketed by 1751.99% in 2022 and then tumbled by 1626.11% in 2025.
  • Over the past 5 years, Angiodynamics' Depreciation & Amortization (CF) (Quarter) stood at $7.3 million in 2021, then rose by 7.4% to $7.8 million in 2022, then fell by 14.49% to $6.7 million in 2023, then rose by 2.66% to $6.9 million in 2024, then dropped by 16.26% to $5.7 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $5.7 million for Q4 2025, versus $6.0 million for Q3 2025 and $5.8 million for Q2 2025.